From Genomic Profile to Treatment: Labcorp’s New BRAF Companion Diagnostic

Article

On August 10, 2026, Labcorp announced FDA approval of PGDx elio tissue complete CDx as a companion diagnostic for advanced melanoma, identifying patients whose tumors harbor BRAF V600E or V600K mutations and who may be candidates for approved BRAF- or BRAF/MEK-targeted therapies. CLICK TO REVIEW RAF SIGNALING The approval is notable because this isn't simply another single-mutation BRAF test. PGDx elio tissue complete is built around comprehensive genomic profiling. The platform analyzes hundreds of cancer-associated genes from tumor tissue and can detect multiple types of genomic alterations while also evaluating biomarkers such as microsatellite instability (MSI) and tumor mutational burden (TMB). Now, within that broader genomic profile, a BRAF V600E/K result can serve an FDA-approved companion-diagnostic function in melanoma. That creates an important distinction. A traditional BRAF assay asks: Does this patient have the mutation? Comprehensive genomic profiling asks: What is the molecular architecture of this tumor—and which of those findings can guide treatment? BRAF V600E illustrates the value. The mutation leaves BRAF capable of persistently driving the MAPK pathway through MEK and ERK. Identifying it therefore connects a molecular finding to a known cancer mechanism and, importantly, to therapies designed to interrupt that mechanism. The platform also uses a distributed kit model, allowing qualified hospitals and clinical laboratories to perform standardized NGS testing within their own facilities rather than requiring every specimen to be sent to a centralized testing laboratory. That combination is what makes this development interesting: Broad genomic profiling + FDA-approved companion diagnostics + distributed testing. The larger story is where precision diagnostics may be heading. Instead of performing isolated tests for individual mutations, a comprehensive genomic platform can characterize the tumor broadly while particular findings become directly connected to therapeutic decisions. For a patient with melanoma, three words on the report— BRAF V600E detected —can now connect genomic testing to mechanism and ultimately to treatment. Sequencing tells us what changed. Precision medicine tells us what to do with that information. CLICK FOR LABCORP PRESS RELEASE